Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc. is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring. The company also produces food safety test kits capable of detecting allergens and gluten residues in food products, serving the needs of food manufacturers and regulatory agencies. Its proprietary testing platforms are designed to deliver rapid, reliable results with user-friendly workflows suitable for both centralized and decentralized laboratory settings.

Founded in the late 1970s and headquartered in Irvine, California, Biomerica maintains a network of direct sales representatives in the United States as well as partnerships with distributors across Europe, Asia and Latin America. The company pursues regulatory clearances such as CE marking and FDA approvals to support its global market expansion. Biomerica’s manufacturing facilities are configured to meet quality standards including ISO 13485, enabling scalable production of diagnostic kits and reagents.

Biomerica is managed by a leadership team with experience in diagnostics research, regulatory affairs and commercial operations. The company continues to invest in product development and strategic collaborations aimed at broadening its assay pipeline and addressing unmet clinical needs. Through ongoing innovation and a focus on building international distribution channels, Biomerica seeks to strengthen its position in the growing in vitro diagnostics market.

Key Stats

• Today's Range: $2.26 to $2.41
• 50-Day Range: $1.49 to $2.37
• 52-Week Range: $1.45 to $3.21
• Volume: 28,914 shs
• Average Volume: 37,604 shs
• Market Capitalization: $7.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Sell

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biomerica has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biomerica has a consensus price target of $9.00, representing about 279.7% upside from its current price of $2.37.

Amount of Analyst Coverage

Biomerica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomerica is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomerica is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently increased by 215.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.44

News Sentiment

Biomerica has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biomerica this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for BMRA on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.5 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Biomerica in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $148,000.00 in company stock, which represents 2.0209% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.28% of the stock of Biomerica is held by institutions.

Company Calendar

• Last Earnings: 8/31/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 10/21/2026
• Fiscal Year End: 5/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 645-2111
• Fax: 949-553-1231
• Employees: 60
• Year Founded: 1971

Price Target and Rating

• Average Price Target for Biomerica: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +285.4%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.78 million
• Net Margins: -84.79%
• Pretax Margin: -84.26%
• Return on Equity: -97.19%
• Return on Assets: -61.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $4.45 million
• Price / Sales: 1.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 2.75

Miscellaneous

• Outstanding Shares: 3,090,000
• Free Float: 2,534,000
• Market Cap: $7.22 million
• Optionable: No Data
• Beta: 0.37